SCHEMBL5338541

SCHEMBL5338541

O=C(Cl)c1cn2cc(F)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.47
APP P05067 1/20 0.44
MAP3K5 Q99683 1/20 0.44
CLK1 P49759 1/20 0.44
DYRK1A Q13627 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
METTL3 Q86U44 1/20 0.42
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
CYP11B1 P15538 3/20 0.40
CYP11B2 P19099 3/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
NR4A2 P43354 1/20 0.38
HRH1 P35367 1/20 0.37
CCR3 P51677 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL870792 0.86 PTGS1 (0.59) EGLN1APPMAP3K5CLK1DYRK1A
Hydrochloric Acid SCHEMBL1422913 0.84 PTGS1 (0.57) EGLN1APPMAP3K5CLK1DYRK1A
SCHEMBL16104299 0.84 CLK1 (0.55) EGLN1APPMAP3K5CLK1DYRK1A
SCHEMBL8176307 0.83 APP (0.48) EGLN1APPMAP3K5CLK1DYRK1A
SCHEMBL13791874 0.79 KDM4E (0.51) PTGS1PTGS2METTL3HRH4HRH3
Hydrochloric Acid SCHEMBL3885254 0.78 KDM4E (0.50) PTGS1PTGS2METTL3HRH4HRH3
SCHEMBL2086460 0.78 PTGS1 (0.50) EGLN1MAP3K5PTGS1PTGS2METTL3
SCHEMBL3365512 0.77 NPC1 (0.68) EGLN1MAP3K5PTGS1PTGS2METTL3
SCHEMBL4098270 0.76 KDM4E (0.64) EGLN1NPC1RAB9A
SCHEMBL21001625 0.76 EGLN1 (0.67) EGLN1APPCLK1DYRK1APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238691-B2 Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity ASTRAZENECA AB (SE) 2007-07-03 US disclosed
EP-1430050-B1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY ASTRAZENECA AB (SE) 2006-08-02 EP disclosed
US-20040242577-A1 Piperdine derivatives and their use as modulators of chemokine (especially ccr3) activity ASTRAZENECA AB (SE) 2004-12-02 US disclosed
EP-1430050-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY AstraZeneca AB (SE) 2004-06-23 EP disclosed
WO-2003024962-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE (ESPECIALLY CCR3) ACTIVITY ASTRAZENECA AB (SE) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242577-A1 Piperdine derivatives and their use as modulators of chemokine (especially ccr3) activity CCR3, CCR1, CCR2 EGLN1 903/4885APP 2973/4885MAP3K5 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.